{"id":"fec-docgemzar-adjuvant-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL4650400","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This regimen combines three chemotherapy drugs: 5-Fluorouracil (5-FU), Epirubicin, and Cyclophosphamide (FEC) followed by Docetaxel and Gemcitabine. The FEC component uses a DNA-damaging anthracycline and alkylating agent approach, while Docetaxel is a microtubule-stabilizing taxane and Gemcitabine is a nucleoside analog. Together, they target cancer cells through multiple mechanisms of cytotoxicity to reduce recurrence risk after surgery.","oneSentence":"FEC-DocGemzar is a combination chemotherapy regimen that uses multiple cytotoxic agents to kill rapidly dividing cancer cells in the adjuvant (post-surgical) setting.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:19.347Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant chemotherapy for early-stage breast cancer"}]},"trialDetails":[{"nctId":"NCT02181101","phase":"PHASE3","title":"Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2005-09","conditions":"Breast Neoplasms","enrollment":3754}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35989,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FEC-DocGemzar adjuvant chemotherapy","genericName":"FEC-DocGemzar adjuvant chemotherapy","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FEC-DocGemzar is a combination chemotherapy regimen that uses multiple cytotoxic agents to kill rapidly dividing cancer cells in the adjuvant (post-surgical) setting. Used for Adjuvant chemotherapy for early-stage breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}